FeesSafety
Pluang+

Takeda's FY2025 revenue dips 1.7% amid generic Vyvanse pressure; eyes growth from new drug launches.

Analyst Insights
18 May 2026, 13:29 WIB
Seeking Alpha
View Source
Bullish
Takeda's FY2025 revenue dips 1.7% amid generic Vyvanse pressure; eyes growth from new drug launches.

Takeda Pharmaceutical reported a 1.7% revenue decline in FY2025 to $28.4 billion, mainly due to generic competition for its drug Vyvanse. The company is implementing a transformation program and cost-cutting measures targeting $1.3 billion in annual savings by FY2028. Takeda's future growth depends on the successful launch of three new drugs: oveporexton, rusfertide, and zasocitinib. Despite current challenges, Takeda's valuation is considered reasonable, supporting a "Buy" recommendation as the market may undervalue these upcoming assets.

More News

Procter & Gamble raises dividend for 70th consecutive year, offering stable income with 2.56% yield.

Procter & Gamble raises dividend for 70th consecutive year, offering stable income with 2.56% yield.

Procter & Gamble has increased its dividend payout for 70 years in a row, demonstrating a strong commitment to rewarding shareholders. The company currently offers a 2.56% dividend yield, which is higher than the S&P 500 average, providing a reliable...

Others
Bullish
1 hour ago
Australian Oilseeds Holdings warned by Nasdaq for not meeting $2.5M equity rule, must submit compliance plan by Jan 2027

Australian Oilseeds Holdings warned by Nasdaq for not meeting $2.5M equity rule, must submit compliance plan by Jan 2027

Australian Oilseeds Holdings Limited received a Nasdaq notification for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting a deficit of over $4.3 million as of June 30, 2026. The company also does not meet alterna...

Market News
Bearish
1 hour ago
Avalo Therapeutics grants stock options to new hires as inducements under Nasdaq rules.

Avalo Therapeutics grants stock options to new hires as inducements under Nasdaq rules.

Avalo Therapeutics has granted inducement stock options totaling 52,000 shares to three new employees, with an exercise price of $6.70 per share. These options vest over four years, starting one year after employment begins, to incentivize and retain...

Company Fundamentals
Neutral
1 hour ago
J&J Snack Foods plans sales growth in 2027 despite rising distribution costs, aided by cost savings and product expansion.

J&J Snack Foods plans sales growth in 2027 despite rising distribution costs, aided by cost savings and product expansion.

J&J Snack Foods reported a 21.6% rise in distribution costs in Q4 2026 due to higher freight and fuel expenses, pressuring near-term earnings. However, the company achieved $25 million in annualized savings through Project Apollo, improving gross mar...

Company Fundamentals
Bullish
1 hour ago
BJ's sales rise 17.7% with 200K new members; plans 30 new stores by 2028 to boost growth.

BJ's sales rise 17.7% with 200K new members; plans 30 new stores by 2028 to boost growth.

BJ's Wholesale Club reported a 17.7% year-over-year increase in net sales for Q3 2026, driven by over 200,000 new members signed up in October and a 6% rise in store traffic during a promotional event. The company reinvested $240 million from a litig...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App